Trends the activity of macrolide and β-lactam antibiotics and resistance development

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 3, 1997, Pages 18-28

  Schito, G C ^a,b   Mannelli, S ^a   Pesce, A ^a   Acar, J ^a,b   Baquero, F ^a,b   Bauernfield, A ^a,b   Berk, S ^a,b   Doern, G ^a,b   Grimm, H ^a,b   Gruneberg R ^a,b   Felmingham, D ^a,b   Lemozy, J ^a,b   Louzao, J Linares ^a,b   Murphy, P ^a,b   Neu, H ^a,b   Chin, U X ^a,b   Russo, G ^a,b   Sewell, D ^a,b   Washington, J ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

lactam; Alexander project; H. influenzae; M. catarrhalis; Macrolide; S. pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN G;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; COMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; EUROPE; HAEMOPHILUS INFLUENZAE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONITORING; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; DRUG RESISTANCE, MICROBIAL; HAEMOPHILUS INFLUENZAE; HUMANS; INTERNATIONAL COOPERATION; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; STREPTOCOCCUS PNEUMONIAE;

EID: 8544230616     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Sykes RB, Matthew M, O'Callaghan CH. R-factor mediated β-lactamase production by Haemophilus influenzae. J Med Microbiol 1975; 8: 437-441.
2. Sykes RB, Matthew M. Detection, assay and immunology of β-lactamases. In Hamilton-Miller JMT, Smith JT, eds. Beta-lactamases. London: Academic Press, 1979: 17-49.
3. Daum RS, Murphey-Corb M, Shapiro E, Dipp S. Epidemiology of ROB β-lactamase among ampicillin-resistant Haemophilus influenzae isolates in the United States. J Infect Dis 1988; 157: 450-455.
4. Scriver SR, Walmsley SL, Kau CL, et al. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrob Agents Chemother 1994; 38: 1678-1680.
5. Markawitz SM. Isolation of an ampicillin-resistant, non-β-lactamase-producing strain of Haemophilus influenzae. Antimicrob Agents Chemother 1980; 17: 80-83.
6. Rubin LG, Medeiros AA, Yolken RH, Moxon ER. Ampicillin treatment failure of apparently β-lactamase-negative Haemophilus influenzae type b meningitis due to novel β- lactamase. Lancet 1981; ii: 1008-1010.
7. Mendelman PM, Chaffin DO, Stull TL, Rubens CE, Mack KD, Smith AL. Characterization of non-β-lactamase- mediated ampicillin resistance in Haemophilus influenzae. Antimicrob Agents Chemother 1984; 26: 235-244.
8. Parr TR, Bryan LE. Mechanism of resistance of an ampicillin-resistant, β-lactamase-negative clinical isolate of Haemophilus influenzae type b to β-lactam antibiotics. Antimicrob Agents Chemother 1984; 25: 747-753.
9. Kayser FH, Morenzoni G, Santanam P. The Second European Collaborative Study on the frequency of antimicrobial resistance in Haemophilus influenzae. Eur J Clin Microbiol Infect Dis 1990; 9: 810-817.
10. Jorgenson JH, Doern GV, Maher LA, Howell AW, Redding JA. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990; 34: 2075-2080.
11. Machka K, Braveny I, Dabernat H, et al. Distribution and resistance patterns of Haemophilus influenzae: a European cooperative study. Eur J Clin Microbiol Infect Dis 1988; 7: 14-24.
12. Tremblay LD, L'Ecuyer J, Provencher P, Bergeron MG and the Canadian Study Group. Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Can Med Assoc J 1990; 143: 895-901.
13. Christensen JJ, Keiding J, Bruun B, Antimicrobial susceptibility and β-lactamase characterisation of Branhamella catarrhalis isolates from 1983/1984 and 1988. APMIS; 98: 1039-1044.
14. Fung C-P, Yeo S-F, Livermore DM. Susceptibility of Moraxella catarrhalis isolates to β-lactam antibiotics in relation to β-lactamase pattern. J Antimicrob Chemother 1994; 33: 215-222.
15. Davies BI, Maesen FPV. The epidemiology of respiratory tract pathogens in southern Netherlands. Eur Resp J 1988; 1: 415-420.
16. Kallings I. Sensitivity of Branhamella catarrhalis to oral antibiotics. Drugs 1986; 32: 17-22.
17. Kislak JW, Ravazi LMB, Daly AK, Finland M. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 1965; 250: 261-268.
18. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-196.
19. Hackenbeck R, Tarpay M, Tomasz A. Multiple changes of penicillin-binding proteins in penicillin resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1980; 17: 364-371.
20. Klugman KP. Pneumococcal resistance to third generation cephalosporins: clinical, laboratory and molecular aspects. Int J Antimicrob Agents 1994; 4: 63-67.
21. Baquero F. Pneumococcal resistance to β-lactam antibiotics: A global geographic overview. Microb Drug Resist 1995; 1: 115-20.
22. Felmingham D, Grüneberg RN and the Alexander Project Collaborative Group. A multicentre collaborative study of the antimicrobial susceptibility of community- acquired, lower respiratory tract pathogens 1992-1993: The Alexander project. J Antimicrob Chemother 1996; 38 (suppl A): 1-57.
23. Goldstein FW, Acar JF and the Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38 (suppl A): 71-84.
24. Doern GV and the Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38 (suppl A): 59-69.
25. Berk SL, Kalbfleisch JH and the Alexander Project Collaborative Group. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA. J Antimicrob Chemother 1996; 38 (suppl A) 85-96.
26. Grüneberg RN, Felmingham D and the Alexander Project Group. Results of the Alexander Project: A continuing multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996; 25: 169-181.
27. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Villanova, PA: NCCLS, 1995; NCCLS Document M100-S6 (Sixth Informational Supplement).
28. Schito G-C, Debbia EA, Pesce A and the Alexander Project Collaborative Group. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992-1993). J Antimicrob Chemother 1996; 38 (suppl A): 87-106.
29. Kolinson G. A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-199). J Chemother 1994; 6: 283-318.
30. Drusano GL, Goldstein FW. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (suppl A): 141-154.
31. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Ped Infect Dis J 1996; 15: 255-259.
32. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25: 215-217.
33. Craig WA. The future - can we learn from the past? Diagn Microbiol Infect Dis 1996; 27: 49-53.
34. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.